SEPN.NASDAQSepterna, INC

10-Q: Septerna Reports Q3 2026 Results, Faces Funding Needs

Sentiment:

Quarterly Report


Septerna, Inc. filed its Q3 2026 Form 10-Q, detailing continued operating losses and a significant accumulated deficit, while highlighting progress in its Novo Nordisk collaboration and advancement of its drug candidates.

Capital raiseThe company has an active at-the-market (ATM) Equity Offering SM Sales Agreement with BofA Securities, Inc., under which it may sell up to $150.0 million of its common stock.During the nine months ended September 30, 2026, the company sold 1,931,790 shares of common stock under the ATM Program, generating net proceeds of $74.8 million.The company expects to require substantial additional funding to finance its operations and expects to continue to incur significant net operating losses for the foreseeable future.
Worse than expectedThe company reported a net loss of $26.6 million for the three months ended September 30, 2026, compared to a net income of $8.2 million in the same period of the prior year.Net loss for the nine months ended September 30, 2026, was $48.3 million, a significant increase from the $38.1 million net loss in the prior year's comparable period.Operating expenses, particularly research and development, have increased substantially, indicating higher investment without a corresponding increase in revenue from product sales.The accumulated deficit has grown to $215.5 million as of September 30, 2026.

Summary

  • Septerna, Inc. reported its financial results for the third quarter and first nine months ended September 30, 2026.
  • The company incurred net losses of $26.6 million and $48.3 million for the three and nine months ended September 30, 2026, respectively.
  • As of September 30, 2026, Septerna had an accumulated deficit of $215.5 million.
  • The company's cash, cash equivalents, and marketable securities totaled $565.2 million, which is expected to fund operations until at least mid-2029.
  • Revenue for the three and nine months ended September 30, 2026, was $18.9 million and $72.2 million, respectively, primarily from the Novo Nordisk collaboration.
  • Research and development expenses increased significantly, driven by clinical and preclinical program advancements.
  • The company announced the selection of SEP-204 as a development candidate and provided updates on its SEP-479 and SEP-631 programs.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative score due to significant operating losses, a substantial accumulated deficit, and the ongoing need for substantial additional funding, despite positive developments in the Novo Nordisk collaboration.

Positives

  • The company has a substantial cash balance of $565.2 million as of September 30, 2026, expected to fund operations until at least mid-2029.
  • Revenue from the Novo Nordisk collaboration was $18.9 million for Q3 2026 and $72.2 million for the nine months ended September 30, 2026.
  • The company received a $195.0 million upfront payment from Novo Nordisk in July 2025.
  • Septerna completed its performance obligations for the first R&D Program with Novo Nordisk and provided the first development candidate in July 2026.
  • The company announced the selection of SEP-204 as an oral small molecule TSHR negative allosteric modulator development candidate.
  • Phase 1 clinical trial for SEP-479 initiated, with data expected in Q1 2027.
  • Proceeds of $61.0 million and $74.8 million were generated from the at-the-market (ATM) offering program during the three and nine months ended September 30, 2026, respectively.

Negatives

  • The company incurred a net loss of $26.6 million for the three months ended September 30, 2026, and $48.3 million for the nine months ended September 30, 2026.
  • An accumulated deficit of $215.5 million was reported as of September 30, 2026.
  • Research and development expenses increased by $12.3 million to $36.6 million for the three months ended September 30, 2026, and by $35.5 million to $101.2 million for the nine months ended September 30, 2026.
  • General and administrative expenses increased by $2.4 million to $9.6 million for the three months ended September 30, 2026, and by $7.4 million to $28.3 million for the nine months ended September 30, 2026.
  • The company expects to continue incurring significant and increasing net operating losses for the next several years.
  • The company requires substantial additional funding to finance its operations.
  • The company has a limited operating history and has not successfully completed any advanced clinical trials.

Risks

  • The company has a limited operating history and has incurred significant operating losses since inception, with expectations of continued losses for the foreseeable future.
  • Substantial additional funding is required to finance operations; failure to raise capital could force delays, reductions, or terminations of research and development programs.
  • The company is early in its development efforts and has not successfully completed any advanced clinical trials, with commercialization years away, if ever.
  • Preclinical and clinical drug development is lengthy, expensive, and uncertain; delays could prevent regulatory approvals and commercialization.
  • Serious adverse events or undesirable side effects of product candidates could lead to discontinuation of development or regulatory refusal.
  • The proprietary Native Complex Platform is based on novel, unproven technologies that may not result in approvable or marketable products.
  • The company faces substantial competition from major pharmaceutical and biotechnology companies.
  • Reliance on third-party manufacturers, CROs, CMOs, and suppliers introduces risks related to their performance, compliance, and supply chain stability.

Future Outlook

The company expects to continue incurring significant and increasing net operating losses for the next several years as it advances its product candidates through preclinical studies and clinical trials, hires personnel, operates as a public company, expands its pipeline, and potentially seeks regulatory approval and commercialization. The company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenditure requirements at least into mid-2029.

Management Comments

  • We expect to continue to incur significant and increasing net operating losses for the next several years as we continue to advance our product candidates through preclinical studies and into clinical trials.
  • We believe our cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2026 will be sufficient to fund our operations and capital expenditure requirements at least into mid-2029.
  • We have incurred significant operating losses since our inception, except for the year ended December 31, 2023. Our revenue to date has been generated solely from research services.

Industry Context

StockSavvy.ai notes that Septerna operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on GPCR-targeted small molecule therapies. The company's reliance on a proprietary platform and its early-stage development pipeline are common characteristics in this industry, where significant investment is required before potential commercialization.

Comparison to Industry Standards

  • The company's net loss of $48.3 million for the nine months ended September 30, 2026, is substantial but not unusual for a clinical-stage biotechnology company investing heavily in R&D.
  • The cash burn rate and the need for future funding are typical for companies at this stage of drug development.
  • The significant increase in R&D expenses ($101.2 million for nine months ended Sep 30, 2026) aligns with industry trends for advancing drug candidates through clinical trials.
  • The collaboration with Novo Nordisk, a major pharmaceutical company, is a common strategy in the industry to de-risk development and access commercialization expertise and capital.

Legal Proceedings

  • The company is not currently a party to any legal proceeding that, if determined adversely, is expected to have a material adverse effect on its business, financial condition, liquidity, or results of operations.

Related Party Transactions

  • A consulting agreement exists with a member of the Company's Board of Directors, with nominal fees paid for the three months ended September 30, 2026, and $0.1 million for the nine months ended September 30, 2026.

Stakeholder Impact

  • Shareholders may experience dilution if additional equity is issued to fund operations.
  • The company's continued losses and need for funding may impact investor confidence and stock price.
  • Employees may be affected by the company's growth plans and the need to attract and retain key personnel.
  • The Novo Nordisk collaboration provides potential future revenue streams through milestones and royalties for shareholders.

Next Steps

  • Continue advancing SEP-479 through Phase 1 clinical trials, with data expected in Q1 2027.
  • Evaluate development strategies for capital-efficient, signal-finding clinical trials for SEP-631.
  • Initiate a Phase 1 clinical trial for SEP-204 in healthy volunteers in Q1 2027, subject to IND-enabling studies and regulatory clearance.
  • Continue to advance other programs in the pipeline.
  • Seek additional funding as needed to support operations and development activities.

Key Dates

DateDescription
2023-09-01Entered into asset purchase agreement with Vertex.
2024-10-24Registration Statement on Form S-1 for IPO declared effective.
2024-10-28Closed Initial Public Offering (IPO).
2025-05-13Entered into global Collaboration and License Agreement with Novo Nordisk A/S.
2025-07-01Novo Collaboration Agreement became effective.
2025-07-XXReceived $12.5 million milestone payment under Vertex Asset Purchase Agreement.
2026-04-13Announced dosing of first participants in Phase 1 clinical trial of SEP-479.
2026-09-10Amendment No. 1 to the Novo Collaboration Agreement.

Recommendation

hold

While Septerna has a promising platform and a significant collaboration with Novo Nordisk, the company continues to incur substantial operating losses and requires significant future funding. The advancement of its pipeline is positive, but the path to profitability remains long and uncertain, warranting a cautious 'hold' stance.

Keywords

biotechnology, clinical-stage, GPCR, drug discovery, small molecule therapies, Native Complex Platform, metabolic diseases, endocrinology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.